Chen Weihong, Li Shaobin, Huang Dongqin, Su Yuchao, Wang Jing, Liang Zhiru
Department of Anxi County Hospital, Quanzhou, China.
Xilin Gol League Central Hospital, Xilin Hot, China.
Front Med (Lausanne). 2024 Jul 18;11:1390803. doi: 10.3389/fmed.2024.1390803. eCollection 2024.
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cancer and currently lacks effective biomarkers. This research aims to analyze and identify RNA editing profile associated with ccRCC prognosis through bioinformatics and experiments.
Transcriptome data and clinical information for ccRCC were retrieved from the TCGA database, and RNA editing files were obtained from the Synapse database. Prognostic models were screened, developed, and assessed using consistency index analysis and independent prognostic analysis, etc. Internal validation models were also constructed for further evaluation. Differential genes were investigated using GO, KEGG, and GSEA enrichment analyses. Furthermore, qPCR was performed to determine gene expression in human renal tubular epithelial cells HK-2 and ccRCC cells A-498, 786-O, and Caki-2.
An RNA editing-based risk score, that effectively distinguishes between high and low-risk populations, has been identified. It includes CHD3| chr17:7815229, MYO19| chr17:34853704, OIP5-AS1| chr15:41590962, MRI1| chr19:13883962, GBP4| chr1:89649327, APOL1| chr22:36662830, FCF1| chr14:75203040 edited sites or genes and could serve as an independent prognostic factor for ccRCC patients. qPCR results showed significant up-regulation of CHD3, MYO19, MRI1, APOL1, and FCF1 in A-498, 786-O, and Caki-2 cells, while the expression of OIP5-AS1 and GBP4 was significantly down-regulated.
RNA editing site-based prognostic models are valuable in differentiating between high and low-risk populations. The seven identified RNA editing sites may be utilized as potential biomarkers for ccRCC.
透明细胞肾细胞癌(ccRCC)是最常见的肾癌类型,目前缺乏有效的生物标志物。本研究旨在通过生物信息学和实验分析并鉴定与ccRCC预后相关的RNA编辑图谱。
从TCGA数据库检索ccRCC的转录组数据和临床信息,并从Synapse数据库获取RNA编辑文件。使用一致性指数分析和独立预后分析等方法筛选、建立和评估预后模型。还构建了内部验证模型进行进一步评估。利用GO、KEGG和GSEA富集分析研究差异基因。此外,进行qPCR以确定人肾小管上皮细胞HK-2和ccRCC细胞A-498、786-O和Caki-2中的基因表达。
已鉴定出一种基于RNA编辑的风险评分,可有效区分高风险和低风险人群。它包括CHD3| chr17:7815229、MYO19| chr17:34853704、OIP5-AS1| chr15:41590962、MRI1| chr19:13883962、GBP4| chr1:89649327、APOL1| chr22:36662830、FCF1| chr14:75203040编辑位点或基因,可作为ccRCC患者的独立预后因素。qPCR结果显示,A-498、786-O和Caki-2细胞中CHD3、MYO19、MRI1、APOL1和FCF1显著上调,而OIP5-AS1和GBP4的表达显著下调。
基于RNA编辑位点的预后模型在区分高风险和低风险人群方面具有重要价值。所鉴定的七个RNA编辑位点可作为ccRCC的潜在生物标志物。